SB-243213

SB-243213 is a drug which acts as a selective inverse agonist for the 5-HT_2C receptor and has anxiolytic effects. It has better than 100x selectivity for 5-HT_2C over all other receptor subtypes tested, and a longer duration of action compared to older 5-HT_2C antagonist ligands.^[1]^[2]^[3]^[4]^[5]^[6]^[7]^[8]

Drug classSerotonin 5-HT_2C receptor inverse agonist

ATC code

None

CAS Number

200940-23-4

PubChem CID

443391

Quick facts Clinical data, Drug class ...

SB-243213
Clinical data

Drug class	Serotonin 5-HT_2C receptor inverse agonist
ATC code	None
Identifiers
IUPAC name 5-methyl-N-(6-[(2-methylpyridin-3-yl)oxy]pyridin-3-yl)-6-(trifluoromethyl)indoline-1-carboxamide
CAS Number	200940-23-4
PubChem CID	443391
ChemSpider	391620
UNII	PA86JD65ZJ
CompTox Dashboard (EPA)	DTXSID0047323
Chemical and physical data
Formula	C₂₂H₁₉F₃N₄O₂
Molar mass	428.415 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CC1=C(C(F)(F)F)C=C(N(C(NC2=CN=C(OC3=C(C)N=CC=C3)C=C2)=O)CC4)C4=C1
InChI InChI=1S/C22H19F3N4O2/c1-13-10-15-7-9-29(18(15)11-17(13)22(23,24)25)21(30)28-16-5-6-20(27-12-16)31-19-4-3-8-26-14(19)2/h3-6,8,10-12H,7,9H2,1-2H3,(H,28,30) Key:ZETBBVYSBABLHL-UHFFFAOYSA-N

References

[1]
Wood MD, Reavill C, Trail B, Wilson A, Stean T, Kennett GA, et al. (August 2001). "SB-243213; a selective 5-HT2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety". Neuropharmacology. 41 (2): 186–99. doi:10.1016/S0028-3908(01)00054-5. PMID 11489455. S2CID 36124035.
[2]
Blackburn TP, Minabe Y, Middlemiss DN, Shirayama Y, Hashimoto K, Ashby CR (December 2002). "Effect of acute and chronic administration of the selective 5-HT2C receptor antagonist SB-243213 on midbrain dopamine neurons in the rat: an in vivo extracellular single cell study". Synapse. 46 (3): 129–39. doi:10.1002/syn.10116. PMID 12325040. S2CID 36766760.
[3]
Di Matteo V, Pierucci M, Esposito E (April 2004). "Selective stimulation of serotonin2c receptors blocks the enhancement of striatal and accumbal dopamine release induced by nicotine administration". Journal of Neurochemistry. 89 (2): 418–29. doi:10.1111/j.1471-4159.2004.02337.x. PMID 15056285. S2CID 29021463.
[4]
Millan MJ, Brocco M, Gobert A, Dekeyne A (February 2005). "Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade". Psychopharmacology. 177 (4): 448–58. doi:10.1007/s00213-004-1962-z. PMID 15289999. S2CID 20866665.
[5]
Berg KA, Navailles S, Sanchez TA, Silva YM, Wood MD, Spampinato U, Clarke WP (October 2006). "Differential effects of 5-methyl-1-2-[(2-methyl-3-pyridyl)oxyl]-5-pyridyl]carbamoyl]-6-trifluoromethylindone (SB 243213) on 5-hydroxytryptamine(2C) receptor-mediated responses". The Journal of Pharmacology and Experimental Therapeutics. 319 (1): 260–8. doi:10.1124/jpet.106.104448. PMID 16807362. S2CID 14889900.
[6]
Monti JM, Jantos H (December 2006). "Effects of the serotonin 5-HT2A/2C receptor agonist DOI and of the selective 5-HT2A or 5-HT2C receptor antagonists EMD 281014 and SB-243213, respectively, on sleep and waking in the rat". European Journal of Pharmacology. 553 (1–3): 163–70. doi:10.1016/j.ejphar.2006.09.027. PMID 17059817.
[7]
Leggio GM, Cathala A, Moison D, Cunningham KA, Piazza PV, Spampinato U (February 2009). "Serotonin2C receptors in the medial prefrontal cortex facilitate cocaine-induced dopamine release in the rat nucleus accumbens". Neuropharmacology. 56 (2): 507–13. doi:10.1016/j.neuropharm.2008.10.005. PMC 3130963. PMID 18977370.
[8]
Kadiri N, Lagière M, Le Moine C, Millan MJ, De Deurwaerdère P, Navailles S (August 2012). "Diverse effects of 5-HT2C receptor blocking agents on c-Fos expression in the rat basal ganglia". European Journal of Pharmacology. 689 (1–3): 8–16. doi:10.1016/j.ejphar.2012.05.022. PMID 22643326.

This article about an anxiolytic is a stub. You can help Wikipedia by adding missing information.

See also

References

Related Articles

Timelines

Top Qs

Fact Checks